Interested in participating in Clinical Trial Studies?

Fill out our quick Pre-Screening Questionnaire below

Active Clinical Trial Studies

Clinical Trial Studies available to participants

Clinical Trial Studies and those who contribute play a role in the development of new treatments for some of our most common and debilitating diseases and conditions.

Patients who participate in Excell’s clinical trial studies have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of psychiatric or medical conditions.

We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating.

Financial compensation may be available to those who qualify and complete visits for clinical trial studies at Excell.

Sign up for a clinical trial study trial today!

Depression Clinical Trial Studies

Clinical Trial Studies Available:

Sponsor:

Alto Neuroscience

Protocol Number:

ALTO-100-201

Summary: The ALTO-100-201 study is evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential study visits.

Eligibility Criteria

Key Inclusion Criteria:

Symptoms of depression for at least 6 weeks prior to entering the study.
Willing to comply with all study assessments and procedures.
Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
Primary symptoms of post-traumatic stress disorder.
Clinically significant medical conditions.
History of substance abuse in the past 3 months.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-70

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table

Sponsor Website: https://www.altoneuroscience.com/

_____________________________________________________________________________________________

Sponsor:

Alto Neuroscience

Protocol Number:

ALTO-100-201 (Decentralized)

Summary: The ALTO-100-201 (Decentralized) study is a partially remote study evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential remote study visits.

Eligibility Criteria

Key Inclusion Criteria:

Symptoms of depression for at least 6 weeks prior to entering the study.
Willing to comply with all study assessments and procedures.
Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
Primary symptoms of post-traumatic stress disorder.
Clinically significant medical conditions.
History of substance abuse in the past 3 months.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

No

Age:

18-70

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table

Sponsor Website: https://www.altoneuroscience.com/

______________________________________________________________________________________________

Sponsor:

Alto Neuroscience

Protocol Number:

ALTO-100-201 (Decentralized)

Summary: The ALTO-100-201 (Decentralized) study is a partially remote study evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential remote study visits.

Eligibility Criteria

Key Inclusion Criteria:

Symptoms of depression for at least 6 weeks prior to entering the study.
Willing to comply with all study assessments and procedures.
Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
Primary symptoms of post-traumatic stress disorder.
Clinically significant medical conditions.
History of substance abuse in the past 3 months.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

No

Age:

18-70

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table

Sponsor Website: https://www.altoneuroscience.com/

____________________________________________________________________________________________

Sponsor:

Janssen Research & Development, LLC

Study Name:

Ventura Study

Protocol Number:

67953964MDD3001

Summary: The Ventura study is a placebo-controlled study evaluating the safety and efficacy of Aticaprant used as adjunctively treatment to an antidepressant. The Ventura study is 13 weeks with 9 study visits in Oceanside, CA.

Eligibility Criteria

Key Inclusion Criteria:

Current symptoms of depression.
Currently taking an antidepressant medication for at least 6 weeks.
Willing to comply with all study assessments and procedures.
Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
History of noncompliance with current antidepressant therapy.
Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-74

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05518149?term=67953964MDD3001&draw=2&rank=1

Sponsor Website: https://www.janssen.com/belgium/rd-janssen

______________________________________________________________________________________________

Sponsor:

Neumora Therapeutics

Protocol Number:

NMRA-335140-301

Summary: The NMRA-335140-301 study is a placebo-controlled study evaluating the safety and efficacy of NMRA-335140 in participants with current depressive symptoms. The study is 16 weeks with 11 scheduled study visits in Oceanside, CA.

Eligibility Criteria

Key Inclusion Criteria:

Symptoms of depression between 4 weeks to 12 months prior to study entry.
Willing to comply with all study assessments and procedures.
Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.

Key Exclusion Criteria:

Diagnosed with post-traumatic stress disorder, bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
Unwillingness to discontinue exclusionary psychiatric medications.
Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-65

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05518149?term=67953964MDD3001&draw=2&rank=1

Sponsor Website: https://neumoratx.com/

__________________________________________________________________________________________

Sponsor:

Axsome Therapeutics

Protocol Number:

AXS-05-MDD-401

Summary: The AXS-05-MDD-401 study is an active-controlled study of AXS-05 for the prevention of relapse of depressive symptoms. The study is initially 10 weeks with 14 visits in Oceanside, CA with the possibility of a 26-week placebo-controlled extension.

Eligibility Criteria

Key Inclusion Criteria:

Symptoms of depression for at least 4 weeks.
Willing to comply with all study assessments and procedures.
Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
Active post-traumatic stress disorder symptoms in the past 3 years.
Low or inadequate response to 2 or more antidepressant medications in the current depressive episode.
Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-65

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT04019704?term=AXS-05&rank=2

Sponsor Website: https://www.axsome.com/

Learn More

Generalized Anxiety Clinical Trial Studies

Clinical Trial Studies Available:

Sponsor:

Sunovion Pharmaceuticals

Protocol Number:

SEP361-226

Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of SEP361 n adults with Generalized Anixety Disorder.

Eligibility Criteria:

Key Inclusion Criteria:

Male or female subject between 18 to 65 years of age.
Symptoms of Generalized Anxiety Disorder over the past 6 months.
Primary focus of treatment is Generalized Anxiety Disorder.

Key Exclusion Criteria:

Diagnosis other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
Previous inadequate response to more than 3 antidepressant treatments.
Any clinically significant unstable medical condition or any clinically significant chronic disease, that would limit the subject’s ability to complete and/or participate in the study.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 to 65

Clinicaltrials.gov Link:

https://clinicaltrials.gov/study/NCT05729373?term=SEP361-226&aggFilters=status:rec&rank=1&tab=table

Sponsor Website:

Sunovion Pharmaceuticals Inc. – New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia

Learn More

Schizophrenia Clinical Trial Studies

Clinical Trial Studies Available:

Sponsor:

Neurocrine

Study Name:

Erudite Study

Protocol Number:

NBI-1065844-CIAS2023

Summary: The Erudite study is evaluating the safety, efficacy, and tolerability of Luvadaxistat in subjects with cognitive impairment associated with schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

Experiencing cognitive impairment with a previous diagnosis of Schizophrenia.
Willing to comply with all study assessments and procedures.
Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 2-6mg Risperidone equivalent.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
Current substance/alcohol abuse.
Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-50

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05182476?term=NBI-1065844-CIAS2023&draw=2&rank=1

Sponsor Website: https://www.neurocrine.com/

_____________________________________________________________________________________________

Sponsor:

Neurocrine

Study Name:

Journey Study

Protocol Number:

NBI-98854-ATS3019

Summary: The Journey study is evaluating the safety, efficacy, and tolerability of Valbenazine as Adjunctive or add on treatment in subjects with schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

Experiencing cognitive impairment with a previous diagnosis of schizophrenia.
Willing to comply with all study assessments and procedures.
Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 3-6mg Risperidone equivalent.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
Current substance/alcohol abuse.
Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 and older

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05110157?term=NBI-98854-ATS3019&draw=2&rank=1

Sponsor Website: https://www.neurocrine.com/

______________________________________________________________________________________________

Sponsor:

Reviva Pharmaceuticals

Study Name:

Recover Study

Protocol Number:

RVP-30-001

Summary: The Recover study is evaluating the safety and efficacy of Brilaroxazine (RP5063) in subjects with acute exacerbation of schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

Experiencing exacerbating symptoms of schizophrenia.
Diagnosis of schizophrenia in in the past 1-20 years.
Willing to comply with all study assessments and procedures.
Currently taking an antipsychotic medication and willing to discontinue.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
History of taking Clozapine.
Current substance/alcohol abuse.
Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-65

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05184335?term=RVP-30-001&rank=1&tab=table

Sponsor Website: https://revivapharma.com/

_____________________________________________________________________________________________

Sponsor:

Click Therapeutics, Inc.

Study Name:

Convoke Study

Protocol Number:

CT-155-R-001

Summary: The Convoke study is evaluating the safety and efficacy of two digital therapeutics as an adjunctive or add on treatment to patients with negative symptoms of schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

Experiencing exacerbating symptoms of schizophrenia.
Current diagnosis of schizophrenia.
Willing to comply with all study assessments and procedures.
Currently taking an antipsychotic medication.
Have a device with updated IOS or Android systems and an active email address.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
History of taking Clozapine.
Current substance/alcohol abuse.
Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 and older

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05838625?term=CT-155-R001&rank=1&tab=table

Sponsor Website: https://www.clicktherapeutics.com/

______________________________________________________________________________________________

Sponsor:

Recognify Life Sciences

Study Name:

Recognify Study

Protocol Number:

C07-03-02

Summary: The Recognify study is a placebo-controlled study evaluating the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

Experiencing cognitive impairment associated with schizophrenia.
Diagnosis of schizophrenia for at least 6 months.
Willing to comply with all study assessments and procedures.
Currently taking an antipsychotic medication for 4 weeks prior to study entry.

Key Exclusion Criteria:

Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
History of taking Clozapine.
Current substance/alcohol abuse.
Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-55

Clinicaltrials.gov Link: https://classic.clinicaltrials.gov/ct2/show/record/NCT05686239

Sponsor Website: https://www.recognify.life/

Learn More

OCD Clinical Clinical Trial Studies

Clinical Trial Studies Available:

Sponsor:

Biohaven Pharmaceuticals

Study Name:

Biohaven Study

Protocol Number:

BHV4157-302

Summary: The Biohaven study is a placebo-controlled study evaluating the safety and efficacy of Troriluzole n adults taking an SSRI to treat symptoms of obsessive-compulsive disorder.

Eligibility Criteria:

Key Inclusion Criteria:

Experiencing moderate to severe symptoms of obsessive-compulsive disorder in the past year.
Currently taking an SSRI medication for 8 weeks prior to study entry. (Zoloft, Prozac, Lexapro, Celexa, ect.)
Willing to stop exclusionary psychiatric medications prior to study entry.

Key Exclusion Criteria:

Lifetime history of bi-polar disorder, schizophrenia, borderline personality disorder or autism spectrum disorders.
Unwilling to discontinue exclusionary medications or comply with study procedures.
Any clinically significant unstable medical condition or any clinically significant chronic disease.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 to 65

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT04641143?term=BHV4157-302&draw=2&rank=1

Sponsor Website:

https://www.biohaven.com/

Learn More

Adolescent Migraine Clinical Trial Studies

Clinical Trial Studies Available:

Sponsor:

AbbVie

Name:

Periscope Study

Protocol Number:

3110-305-002

Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Ubrogepant in acute treatment of migraine with or without aura in children and adolescents.

Eligibility Criteria

Key Inclusion Criteria:

History of 1 to 14 migraine attacks per month with moderate to severe headaches in each of the 2 months prior to study entry.
Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.

Key Exclusion Criteria:

Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

12-17

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/study/NCT05125302?term=3110-305-002&draw=2&rank=2

Sponsor Website: https://www.abbvie.com/who-we-are.html?utm_medium=psearch&utm_campaign=corprepppp_2023&utm_source=google&utm_content=igp&utm_term=brandcore&cid=ppc_CV5d23f5fe9b1d494480b4c5bdc9a98b4d&gclid=CjwKCAjw-b-kBhB-EiwA4fvKrPKcFLoo52XYUNnDKWdQW20OpCRUZU5roVmk_UOLWa

_____________________________________________________________________________________________

Sponsor:

AbbVie

Name:

Kaleidoscope Study

Protocol Number:

M21-201

Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Atogepant for the preventive treatment of episodic migraine in children and adolescence.

Eligibility Criteria

Key Inclusion Criteria:

History of 4 to 14 migraine attacks per month with less than 15 headache days 28 days prior to study entry.
Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.

Key Exclusion Criteria:

Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.
History of migraine aura with impairment of level of consciousness, hemiplegic migraine, or retinal migraine.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

12-17

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05711394?term=M21-201&draw=2&rank=1

Sponsor Website: https://www.abbvie.com/who-we-are.html?utm_medium=psearch&utm_campaign=corprepppp_2023&utm_source=google&utm_content=igp&utm_term=brandcore&cid=ppc_CV5d23f5fe9b1d494480b4c5bdc9a98b4d&gclid=CjwKCAjw-b-kBhB-EiwA4fvKrPKcFLoo52XYUNnDKWdQW20OpCRUZU5roVmk_UOLWa

Learn More